News
Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport
Promising non-clinical results support Phase 1 clinical study…
Destiny Pharma: Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme
Positive feedback from European Medicines Agency on XF-73 Nasal…
vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury
Improved neurologic outcome in young adults (18-39 years)…
Novo Nordisk Fonden – Record year for industrial biotechnology grants and investments
Biotechnology – and in particular industrial biotechnology…
Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs
Synaffix to provide access to proprietary antibody-drug conjugate…
eTheRNA Announces Research Agreement with Merck to access mRNA technologies
eTheRNA immunotherapies NV (“eTheRNA”) is pleased to announce…
Destiny Pharma announces positive results in XF-73 Dermal safety study from ongoing agreement with US Government’s NIAID
Brighton, United Kingdom, 1 February 2022 - Destiny Pharma plc…
CellCentric secures investment from the American Cancer Society’s impact venture capital fund
Inobrodib is the first drug to target p300/CBP, a new way to…
ImaginAb Inc. and DongCheng Pharmaceutical Group Announce Plans for a CD8 ImmunoPET Commercial Partnership
Both organizations working together to form a commercial partnership…
Destiny Pharma Significant clinical and commercial opportunity of NTCD-M3 confirmed by positive data from US research study and new market research
Significant clinical and commercial opportunity of NTCD-M3 confirmed…
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Top-line Data Expected in the Third Quarter of 2022
LONDON and…
Destiny Pharma Lancet Report
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Important…
Amber Implants Closes US$10 M Series A Financing
The Hague, Netherlands, 19 January 2022: Amber Implants, an…
Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US
Emcitate® (tiratricol) is the first potential treatment of…
Destiny Pharma Strategy/Company/Ops Update
Brighton, United Kingdom, 17 January 2022 – Destiny Pharma…
Novo Seeds Provides Business Update on a Record Year – Building Exceptional Companies for Global Impact
Over US$ 550 million raised by portfolio companies in 2021
…
BioInnovation Institute Awarded Grant to Launch a New Initiative Focused on Women’s Health
COPENHAGEN, Denmark, 11 January 2022 – BioInnovation Institute…
Future Fertility Raises Series A to Progress First-In-Class AI-Enabled Fertility Solutions to Improve IVF Outcomes
First company to develop an AI product to predict egg viability…
Novo Holdings – Grant of DKK 200 million will create better future prospects for young Syrian refugees in Jordan
Youth unemployment in Jordan is record high, and up to 50% of…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
